Sokol ES - Search Results

1

The Molecular Landscape of Gastric Cancers for Novel Targeted Therapies from Real-World Genomic Profiling.

Yamamoto H, Arai H, Oikawa R, Umemoto K, Takeda H, Mizukami T, Kubota Y, Doi A, Horie Y, Ogura T, Izawa N, Moore JA, Sokol ES, Sunakawa Y. Yamamoto H, et al. Among authors: sokol es. Target Oncol. 2024 May;19(3):459-471. doi: 10.1007/s11523-024-01052-1. Epub 2024 Apr 13. Target Oncol. 2024. PMID: 38613733

2

Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.

Porta C, Pradelli L, Sicari E, Castellani S, Sivakumar S, Sokol E, Montesion M, Wieland T, Rambichler J, Minari R, Tiseo M. Porta C, et al. Lung Cancer. 2023 Nov;185:107359. doi: 10.1016/j.lungcan.2023.107359. Epub 2023 Sep 4. Lung Cancer. 2023. PMID: 37703610

3

Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests.

Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K. Miura K, et al. Among authors: sokol es. J Natl Compr Canc Netw. 2024 Aug 8;22(7):e247021. doi: 10.6004/jnccn.2024.7021. J Natl Compr Canc Netw. 2024. PMID: 39116914

4

Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.

Özgü E, Kaplan BG, Sivakumar S, Sokol ES, Aydın E, Tokat ÜM, Adibi A, Karakoç EG, Hu J, Kurzrock R, Demiray M. Özgü E, et al. Among authors: sokol es. BJC Rep. 2024 Oct 8;2(1):77. doi: 10.1038/s44276-024-00086-2. BJC Rep. 2024. PMID: 39516363 Free PMC article.

5

Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.

Sivakumar S, Jin DX, Tukachinsky H, Murugesan K, McGregor K, Danziger N, Pavlick D, Gjoerup O, Ross JS, Harmon R, Chung J, Decker B, Dennis L, Frampton GM, Molinero L, Oesterreich S, Venstrom JM, Oxnard GR, Hegde PS, Sokol ES. Sivakumar S, et al. Among authors: sokol es. Nat Commun. 2022 Dec 5;13(1):7495. doi: 10.1038/s41467-022-35245-x. Nat Commun. 2022. PMID: 36470901 Free PMC article.

6

Ancestry-associated co-alteration landscape of KRAS and EGFR-altered non-squamous NSCLC.

Sisoudiya SD, Houle AA, Fernando T, Wilson TR, Schutzman JL, Lee J, Schrock A, Sokol ES, Sivakumar S, Shi Z, Pathria G. Sisoudiya SD, et al. Among authors: sokol es. NPJ Precis Oncol. 2024 Jul 20;8(1):153. doi: 10.1038/s41698-024-00644-4. NPJ Precis Oncol. 2024. PMID: 39033203 Free PMC article.

7

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.

Orme JJ, Taza F, De Sarkar N, Tewari AK, Arsalan Naqvi S, Riaz IB, Childs DS, Omar N, Adra N, Ashkar R, Cheng HH, Schweizer MT, Sokolova AO, Agarwal N, Barata P, Sartor O, Bastos D, Smaletz O, Berchuck JE, McClure H, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Mehra N, Nelson PS, Hwang J, Dehm SM, Shi Q, Fleischmann Z, Sokol ES, Elliott A, Huang H, Bryce A, Marshall CH, Antonarakis ES. Orme JJ, et al. Among authors: sokol es. Eur Urol Oncol. 2024 Aug;7(4):877-887. doi: 10.1016/j.euo.2023.11.014. Epub 2023 Dec 9. Eur Urol Oncol. 2024. PMID: 38072760

8

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma.

Rugo HS, Raskina K, Schrock AB, Madison RW, Graf RP, Sokol ES, Sivakumar S, Lee JK, Fisher V, Oxnard GR, Tukachinsky H. Rugo HS, et al. Among authors: sokol es. Clin Cancer Res. 2023 Mar 14;29(6):1056-1067. doi: 10.1158/1078-0432.CCR-22-2115. Clin Cancer Res. 2023. PMID: 36321996 Free PMC article.

9

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations.

Sivakumar S, Jin DX, Rathod R, Ross J, Cantley LC, Scaltriti M, Chen JW, Hutchinson KE, Wilson TR, Sokol ES, Vasan N. Sivakumar S, et al. Among authors: sokol es. Clin Cancer Res. 2023 Mar 14;29(6):1125-1136. doi: 10.1158/1078-0432.CCR-22-2270. Clin Cancer Res. 2023. PMID: 36595567 Free PMC article.

10

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.

Hutchinson KE, Chen JW, Savage HM, Stout TJ, Schimmoller F, Cortés J, Dent S, Harbeck N, Jacot W, Krop I, Trabucco SE, Sivakumar S, Sokol ES, Wilson TR. Hutchinson KE, et al. Among authors: sokol es. Genome Med. 2023 Apr 26;15(1):28. doi: 10.1186/s13073-023-01181-8. Genome Med. 2023. PMID: 37101291 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

105 results

Search Page

Filters